Patent Application
20210252115
Prostate cancer (CaP) growth and progression rely on the interaction between androgen receptor (AR) and the testicular androgens testosterone (T) and dihydrotestosterone (DHT). Almost all men who are present with CaP and some men who fail potentially curative therapy are treated with androgen deprivation therapy (ADT). ADT lowers circulating T levels, deprives AR of ligand and induces CaP regression. However, when ADT is not curative, intratumoral androgen levels are sufficient to activate AR and CaP recurs as lethal castration-recurrent/resistant CaP (CRPC). One mechanism that may contribute to CaP resistance to ADT is intratumoral intracrine androgen metabolism, which is defined as the conversion of weak adrenal androgens to T or DHT. There are 3 androgen metabolism pathways to DHT. The frontdoor pathway uses adrenal androgens dehydroepiandrosterone (DHEA) or androstenedione (ASD), to generate T, which is 5α-reduced to DHT by 5α-reductases (SRD5A). The backdoor pathways are defined by DHT generation without using T as substrate. Previous work from our laboratory and others has demonstrated that CaP cells use the primary or secondary backdoor androgen metabolism pathways to produce DHT. The terminal step in the primary backdoor pathway involves conversion of 5α-androstane-3α, 17β-diol (androstanediol) to DHT. Androstanediol is converted to DHT by the 3α-oxidoreductases, 17β-hydroxysteroid dehydrogenase-6 (HSD17B6), retinol dehydrogenase 5 (RDH5), RDH16 and dehydrogenase/reductase family member 9 (DHRS9). The secondary backdoor pathway involves the conversion of DHEA to ASD by HSD3βs, ASD to androstanedione (5α-dione) by SRD5A and 5α-dione to DHT by 3α-oxidoreductases.
Androgen metabolism inhibitors, such as the SRD5A1, 2 or 3 inhibitor, dutasteride, or CYP17A1 inhibitor, abiraterone, inhibit their targets, but neither is very effective clinically against CaP. Dutasteride inhibits SRD5A activity, but intratumoral DHT levels are not depleted. CYP17A1 metabolizes steroids, such as pregnenolone or progesterone, and adrenal androgens, like DHEA, that feed into the 3 androgen metabolism pathways to generate T or DHT. CYP17A1 inhibitors, such as abiraterone, decrease intratumoral DHT levels, but abiraterone was shown to extend survival only approximately 4 months. CaP resistance to abiraterone may be attributed to several mechanisms that include enzyme redundancy, progesterone accumulation that leads to increased CYP17A1 expression or generation of AR splice variants.
Because there are several 3α-oxidoreductases involved in the conversion of androstanediol to DHT, currently no consideration is given to inhibition of these enzymes as a treatment approach.
In the present disclosure, we identified that the 3α-oxidoreductases, HSD17B6, RDH16, DHRS9, and RDH5, possess highly conserved catalytic amino acid residues. We further determined that the four 3α-oxidoreductases' catalytic activity is critical for conversion of androsterone (AND) to 5α-dione (5α-dione) and androstanediol to DHT, and that these 4 enzymes share a common catalytic consensus sequence. Further we demonstrated that inhibition of the terminal steps of the frontdoor and primary backdoor pathways to DHT synthesis is useful for treatment of advanced CaP. This approach should lower DHT more effectively than inhibitors of 5α-reductases and/or CYP17A1.
In one aspect, this disclosure provides a method of inhibiting activity or expression of one or more 3α-oxidoreductase enzymes that share a common catalytic site and convert androstanediol to DHT, the method comprising introducing one or more agents into cells that comprise the one or more 3α-oxidoreductase enzymes, wherein said one or more agents: i) inhibit function of one or more said enzymes; ii) inhibit translation of mRNA encoding said enzymes; iii) disrupt or delete genes encoding said enzymes; or a combination thereof. For example, the agent of i) comprises a small molecule inhibitor that inhibits a catalytic site that is shared among the enzymes, the agent of ii) comprises an RNAi agent, said agent being an antisense oligonucleotide, a microRNA, an shRNA, or a ribozyme, and the agent of iii) comprises a CRISPR system, the CRISPR system comprising at least one Cas enzyme and at least one guide RNA that targets one or more genes encoding said one or more enzymes, wherein the CRISPR system disrupts or deletes said one or more genes, wherein optionally two of said enzymes are inhibited concurrently, or two or more of said enzymes are inhibited sequentially, wherein the CRISPR system optionally further comprises DNA repair templates that are recombined into said genes to thereby disrupt or delete the genes. For example, said enzymes are at least one of HSD17B6, RDH16, DHRS9, or RDH5.
In embodiments, activity of 1, 2, 3, or 4 of the enzymes is inhibited. In an embodiment, the activity of at least RDH5 is inhibited. In embodiments, the activity of RDH5 and at least 1, 2, or 3 of HSD17B6, RDH16, and DHRS9 is inhibited. In embodiments, the activity of at least two of the enzymes is inhibited concurrently.
In one aspect, the inhibition of the activity or expression of one or more of the described 3α-oxidoreductase enzymes causes inhibition of growth of CaP cells, wherein the one or more enzymes are HSD17B6, RDH16, DHRS9, or RDH5.
The present disclosure is based on the identification of a common catalytic site for the four 3α-oxidoreductases that catalyze the terminal step of the primary backdoor pathway in the conversion of androstanediol to DHT. This disclosure provides methods for inhibiting activity or expression of one or more 3α-oxidoreductase enzymes that share a common catalytic site and convert androstanediol to DHT, the method comprising introducing one or more agents into cells that comprise the one or more 3α-oxidoreductase enzymes, wherein said one or more agents: i) inhibit function of one or more said enzymes; ii) inhibit translation of mRNA encoding said enzymes; iii) disrupt or delete genes encoding said enzymes; or a combination thereof. For example, the agent may inhibit 1, 2, 3, or 4, or more of the known 3α-oxidoreductases. The 3α-oxidoreductases are at least one of HSD17B6, RDH16, DHRS9, or RDH5, or others. In one aspect the activity of all of the enzymes is inhibited, and in one aspect said enzyme is at least RDH5. In embodiments, the activity of RDH5 and at least 1, 2, or 3 of HSD17B6, RDH16, and DHRS9 is inhibited.
By referring to 3α-oxidoreductase enzymes having a common catalytic site is meant that their amino acid sequence comprises a consensus sequence for the catalytic site. The consensus sequence can be GGYX1X2SK (SEQ ID NO: 1), wherein X1X2 can be any amino acids. For example, X1 may be C or T, and X2 may be V, I or P. These amino acids are found in positions 174-180 of the amino acid sequences of the HSD17B6, RDH16, DHRS9 and RDH5 3α-oxidoreductase enzymes (Accession Nos. NP 003716.2, NP 003699.3, NP 002896.2, and NP 954674.1 respectively).
This disclosure provides a method of inhibiting activity or expression of one or more 3α-oxidoreductase enzymes that share a common catalytic site and convert androstanediol to DHT, wherein the inhibition of the activity of one or more 3α-oxidoreductase enzymes causes inhibition of growth of CaP cells. The 3α-oxidoreductases are at least one of HSD17B6, RDH16, DHRS9, or RDH5, or others. The activity of one or more 3α-oxidoreductases may be inhibited by i) inhibiting function of one or more said enzymes; ii) inhibiting translation of mRNA encoding said enzymes; iii) disrupting or deleting genes encoding said enzymes; or a combination thereof. For example, the agent of i) comprises a small molecule inhibitor that inhibits the catalytic site that is shared among the enzymes, the agent of ii) comprises an RNAi agent, said agent being an antisense oligonucleotide, a microRNA, an shRNA, or a ribozyme, and the agent of iii) comprises a CRISPR system, the CRISPR system comprising at least one Cas enzyme and at least one guide RNA that targets one or more genes encoding said one or more enzymes, and wherein the CRISPR system disrupts or deletes said one or more genes, and said one or more enzymes are optionally inhibited sequentially or concurrently, wherein the CRISPR system optionally further comprises DNA repair templates that are introduced into said genes to thereby disrupt or delete the said one or more enzymes are inhibited sequentially. In embodiments, at least 1, 2, 3, or 4 of the described enzymes are inhibited concurrently. In embodiments, two of said enzymes are inhibited concurrently, or two or more of said enzymes are inhibited sequentially.
In embodiments, the target genes encode the consensus sequence GGYX1X2SK (SEQ ID NO: 1) for the catalytic site of the common amino acids. For example, the catalytic activity of this site may be interfered with, or the Y and the K may be changed to another amino acid, which in non-limiting embodiments includes altering a DNA coding sequence that is encompassed by the consensus sequence.
This disclosure provides a method of reducing the conversion of androstanediol to DHT in prostate cells comprising inhibiting the activity of one or more 3α-oxidoreductases. The enzymes are at least one of HSD17B6, RDH16, DHRS9, or RDH5.
This disclosure provides a method of treating CaP comprising administering to an individual who has CaP a therapeutically effective amount of an inhibitor that i) inhibits function of one or more 3α-oxidoreductase enzymes that catalyze the conversion of androstanediol to DHT and have the consensus catalytic site sequence; ii) inhibits translation of mRNA encoding said enzymes; iii) disrupts or deletes genes encoding said enzymes; or a combination thereof, wherein said enzymes comprises 1, 2, 3, 4, or more 3α-oxidoreductase enzymes, as described above. In one embodiment, said enzymes are one or more of HSD17B6, RDH16, DHRS9, or RDH5, and in one aspect, the activity of all of the enzymes is inhibited. In an embodiment, the activity of at least RDH5 and 1, 2, or 3 of the described enzymes is inhibited. The method may further comprise administering to the individual a composition comprising another therapeutic effective against CaP. For example, the method may comprise administering to the individual a composition comprising dutasteride and/or abiraterone, which may be administered concurrently or sequentially with the 3α-oxidoreductase enzymes inhibitor.
This disclosure provides a method of inhibition of growth of CaP cells comprising contacting the cells with an effective amount of an inhibitor that i) inhibits function of one or more 3α-oxidoreductase enzymes that catalyze the conversion of androstanediol to DHT and have the consensus catalytic site sequence; ii) inhibits translation of mRNA encoding said enzymes; iii) disrupts or deletes genes encoding said enzymes; or a combination thereof. Said enzymes can comprise 1, 2, 3, 4 or more 3α-oxidoreductase enzymes. In one embodiment, said enzymes are at least one of HSD17B6, RDH16, DHRS9, or RDH5, and in one aspect, the activity of all of the enzymes is inhibited, and in one aspect, said enzyme is RDH5. In embodiments, the activity of RDH5 and at least 1, 2, or 3 of HSD17B6, RDH16, and DHRS9 is inhibited. The method may further comprise contacting the cells with a composition comprising another inhibitor of growth of CaP cells. For example, the method may comprise contacting the cells with a composition comprising dutasteride and/or abiraterone. The cells may be contacted concurrently or sequentially with the 3α-oxidoreductase enzymes inhibitor.
The activity of one or more 3α-oxidoreductase enzymes can be inhibited by contact with a composition comprising a single inhibitor of the consensus catalytic sequence, wherein said inhibitor: i) inhibits function of one or more said enzymes; ii) inhibits translation of mRNA encoding said enzymes; iii) disrupts or deletes genes encoding said enzymes; or a combination thereof. For example, the inhibitor of i) comprises a small molecule inhibitor that inhibits the catalytic site that is shared among the enzymes, the inhibitor of ii) comprises an RNAi agent, said agent being an antisense oligonucleotide, a microRNA, an shRNA, or a ribozyme, and the inhibitor of iii) comprises a CRISPR system, the CRISPR system comprising at least one Cas enzyme and at least one guide RNA that targets one or more genes encoding said one or more enzymes, wherein the CRISPR system disrupts or deletes said one or more genes, and said one or more enzymes are optionally inhibited sequentially or concurrently, wherein the CRISPR system further comprises DNA repair templates that are recombined into said genes to thereby disrupt or delete the genes, and said one or more enzymes are inhibited sequentially. For example, said enzymes are at least one of HSD17B6, RDH16, DHRS9, or RDH5, and in one aspect the activity of all of the enzymes is inhibited, and in one aspect said enzyme is RDH5. In embodiments, two of said enzymes are inhibited concurrently, or two or more of said enzymes are inhibited sequentially. The composition can comprise other inhibitors of growth of cancer cells such as dutasteride and/or abiraterone.
The disclosure provides compositions for use in the inhibition of growth or CaP cells or treatment of CaP. The compositions comprise inhibitors that i) inhibit function of one or more 3α-oxidoreductase enzymes that catalyze the conversion of androstanediol to DHT and have the consensus catalytic site sequence; ii) inhibit translation of mRNA encoding said enzymes; iii) disrupt or delete genes encoding said enzymes; or a combination thereof. For example, the inhibitors may inhibit at least one of HSD17B6, RDH16, DHRS9, or RDH5, and in one aspect, the activity of all of the enzymes is inhibited, and in one aspect, said enzyme is RDH5. In embodiments, the activity of RDH5 and at least 1, 2, or 3 of HSD17B6, RDH16, and DHRS9 is inhibited. The composition may further comprise another inhibitor of growth of CaP cells, such as dutasteride and/or abiraterone.
The disclosure provides CaP cells in which inhibitors of one or more 3α-oxidoreductase enzymes have been introduced, which i) inhibit function of one or more 3α-oxidoreductase enzymes that catalyze the conversion of androstanediol to DHT and have the consensus catalytic site sequence; ii) inhibit translation of mRNA encoding said enzymes; iii) disrupt or delete genes encoding said enzymes; or a combination thereof. In one embodiment, said enzymes are at least one of HSD17B6, RDH16, DHRS9, or RDH5, and in one aspect, the activity of all of the enzymes is inhibited, and in one aspect, said enzyme is RDH5. In embodiments, the activity of RDH5 and at least 1, 2, or 3 of HSD17B6, RDH16, and DHRS9 is inhibited.
The disclosure also provides prostate cells in which one or more of the following enzymes have been inactivated, or are non-functional or minimally functional: HSD17B6, RDH16, DHRS9, or RDH5. The enzymes may have been inactivated, or rendered non-functional or minimally functional by i) inhibiting function of one or more said enzymes; ii) inhibiting translation of mRNA encoding said enzymes; iii) disrupting or deleting genes encoding said enzymes; or a combination thereof. In one aspect, the activity of all of the enzymes is inhibited, and in one aspect, said enzyme is RDH5. In embodiments, the activity of RDH5 and at least 1, 2, or 3 of HSD17B6, RDH16, and DHRS9 is inhibited.
The present disclosure provides a method for identifying agents that can synergistically, with other anti-CaP agents (such as, for example, dutasteride and/or abiraterone), inhibit the activity or expression of 3α-oxidoreductase enzymes. For example, the agents may be identified by contacting CaP cells with candidate agents to determine if CaP cells are synergistically inhibited upon further contact with dutasteride and/or abiraterone.
The term “therapeutically effective amount” as used herein refers to an amount of an agent sufficient to achieve, in a single or multiple doses, the intended purpose of treatment. For example, an effective amount to treat CaP is an amount sufficient to kill CaP cells. The exact amount desired or required will vary depending on the particular compound or composition used, its mode of administration and the like. Appropriate effective amount can be determined by one of ordinary skill in the art informed by the instant disclosure using only routine experimentation.
Within the meaning of the disclosure, “treatment” includes the treatment of prophylaxis as well as the treatment of acute or chronic signs, symptoms and/or malfunctions. The treatment can be orientated symptomatically, for example, to suppress symptoms. It can be effected over a short period, be oriented over a medium term, or can be a long-term treatment, for example within the context of a maintenance therapy.
Inhibition of the 3α-oxidoreductases can comprise pharmacological inhibition of their activity. In certain approaches, pharmacologic inhibition comprises use of enzyme-specific small molecules for enzymatic activity inhibition, or neutralizing antibodies, or other enzyme-specific biologics.
In one aspect, the disclosure includes inhibiting the expression of the one or more 3α-oxidoreductase genes and inhibiting translation of mRNA encoding the one or more 3α-oxidoreductase genes. Thus, in embodiments, the disclosure includes disruption or deletion of the one or more 3α-oxidoreductase genes. Disruption or deletion of the genes may be performed using a chromosome editing approach, one non-limiting example of which comprises a CRISPR-based approach.
In one aspect, a CRISPR-based method for genome editing is used to disrupt or delete all or a portion of the one or more 3α-oxidoreductase genes, or is used to insert one or more mutations into the genes, such that expression of one or more functional 3α-oxidoreductase enzymes is reduced or preferably eliminated. Representative and non-limiting demonstrations of this approach are described below.
In certain aspects, any suitable CRISPR system is used. In embodiments, a Type II CRISPR system is used. In embodiments, a Cas9 enzyme is used. In embodiments, the Cas9 is a S. pyogenes Cas9. Alternatives to Cas9 are known in the art and may be adapted for use in embodiments of this disclosure, such as Cas12a (formerly Cpf1), and may include enhanced CRISPR techniques, such as prime editing.
In one aspect, the disclosure comprises introducing into cells a CRISPR enzyme and a targeting RNA directed to one or more 3α-oxidoreductase genes, which may be a CRISPR RNA (crRNA) or a guide RNA, such as sgRNA. The sequence of the targeting RNA has a segment that is the same as or complementarity to any suitable CRISPR site in the one or more 3α-oxidoreductase genes. In this regard, for Cas9 editing, the target sequence comprises a specific sequence on its 3′ end referred to as a protospacer adjacent motif or “PAM”. In an embodiment a CRISPR Type II system is used, and the target sequences therefore conform to the well-known N12-20NGG motif, wherein the NGG is the PAM sequence. Thus, in embodiments, a target RNA will comprise or consist of a segment that is from 12-20 nucleotides in length, which is the same as or complementary to a DNA target sequence (a spacer) in the one or more 3α-oxidoreductase genes. The 12-20 nucleotides directed to the spacer sequence will be present in the targeting RNA, regardless of whether the targeting RNA is a crRNA or a guide RNA. In embodiments, a separate trans-activating crRNA (tracrRNA) can be used to assist in maturation of a crRNA targeted to the one or more 3α-oxidoreductase genes. Introduction a CRISPR system into cells, which include but are not necessarily limited to prostate cells, will result in binding of a targeting RNA/Cas9 (or other suitable enzyme) complex to the one or more 3α-oxidoreductase genes target sequence so that the Cas9 can cut both strands of DNA causing a double strand break. The double stranded break can be repaired by non-homologous end joining DNA repair, or by a homology directed repair pathway, which will result in either insertions or deletions at the break site, or by using a repair template to introduce mutations, respectively. Double-stranded breaks can also be introduced into the one or more 3α-oxidoreductase genes by expressing Transcription Activator-Like Effector Nucleases (TALENs) in the cells, Zinc-Finger Nucleases (ZFNs) in cells.
In one aspect, expression is inhibited by inhibiting transcription or translation of RNA encoding the one or more 3α-oxidoreductases. In embodiments, transcription of mRNA is inhibited by binding of a protein, such as an enzymatically inactive CRISPR enzyme, e.g., dCas9, to the DNA encoding the one or more 3α-oxidoreductases mRNA, or DNA controlling their transcription. In one aspect, the one or more enzymes are inhibited sequentially. In embodiments, two of said enzymes are inhibited concurrently, or two or more of said enzymes are inhibited sequentially.
In one aspect, the disclosure includes interfering with the transcription or translation of mRNA encoding one or more of the 3α-oxidoreductases and as a result reducing expression of the enzymes. Reducing mRNA can involve introducing into cells that express the enzymes a molecule such as a polynucleotide that can inhibit translation of enzyme-encoding mRNA, and/or can participate in and/or facilitate RNAi-mediated reduction of the mRNA. For example, an antisense polynucleotide can be used to inhibit translation of the mRNA. Antisense nucleic acids can be DNA or RNA molecules that are complementary to at least a portion of the targeted mRNA. For example, the DNA or RNA molecules may be complementary to the portion of the mRNA that encodes for the common catalytic region of the one or more 3α-oxidoreductases. The DNA or RNA molecules may be from 5 to 15 nucleotides. The polynucleotides for use in targeting mRNA may be modified, such as, for example, to be resistant to nucleases.
As an example, this disclosure includes RNAi-mediated reduction in mRNA. RNAi-based inhibition can be achieved using any suitable RNA polynucleotide that is targeted to an enzyme-mRNA. For example, a single stranded or double stranded RNA, wherein at least one strand is complementary to the targeted mRNA, can be introduced into the cell to promote RNAi-based degradation of target mRNA. MicroRNA (miRNA) targeted to the mRNA can be used. A ribozyme that can specifically cleave target mRNA can be used. Small interfering RNA (siRNA) can be used. siRNA (or ribozymes) can be introduced directly, for example, as a double stranded siRNA complex, or by using a modified expression vector, such as a lentiviral vector, to produce an shRNA. As is known in the art, shRNAs adopt a typical hairpin secondary structure that contains a paired sense and antisense portion, and a short loop sequence between the paired sense and antisense portions. shRNA is delivered to the cytoplasm where it is processed by DICER into siRNAs. siRNA is recognized by RNA-induced silencing complex (RISC), and once incorporated into RISC, siRNAs facilitate cleavage and degradation of targeted mRNA. A shRNA polynucleotide used to suppress mRNA expression can comprise or consist of between 45-100 nucleotides, inclusive, and including all integers between 45 and 100, and all ranges there between. As an example, the portion of the shRNA that is complementary to the target mRNA can be from 21-29 nucleotides, inclusive, and including all integers between 21 and 29.
For delivering siRNA via shRNA, modified lentiviral vectors can be made and used according to standard techniques, given the benefit of the present disclosure. In certain approaches, modified lentiviruses are used to stably infect target cells, and may integrate into a chromosome in the targeted cells. For example, see Titus M A, Zeithaml B, Kantor B, Li X, Haack K, Moore D T, Wilson E M, Mohler J L, Kafri T. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent CaP. PLoS One 2012; 7(1): e30192. In embodiments, a CRISPR system or an RNAi medicated approach can be achieved using a recombinant adenovirus, many of which are known in the art and can be adapted for use in embodiments of the disclosure.
Other compositions to inhibit one or more enzymes may be used in the form of pharmaceutical compositions. The pharmaceutical composition of the invention may be administered by any route that is appropriate, including but not limited to parenteral or oral administration. The pharmaceutical compositions for parenteral administration include solutions, suspensions, emulsions, and solid injectable compositions that are dissolved or suspended in a solvent before use. The injections may be prepared by dissolving, suspending or emulsifying one or more of the active ingredients in a diluent. Examples of diluents are distilled water for injection, physiological saline, vegetable oil, alcohol, and a combination thereof. Further, the injections may contain stabilizers, solubilizers, suspending agents, emulsifiers, soothing agents, buffers, preservatives, etc. The injections, are sterilized in the final formulation step or prepared by sterile procedure. The pharmaceutical composition of the invention may also be formulated into a sterile solid preparation, for example, by freeze-drying, and may be used after sterilized or dissolved in sterile injectable water or other sterile diluent(s) immediately before use. The compositions described can include one or more standard pharmaceutically acceptable carriers. Some examples herein of pharmaceutically acceptable carriers can be found in: Remington: The Science and Practice of Pharmacy (2005) 21st Edition, Philadelphia, Pa. Lippincott Williams & Wilkins.
The method of the present disclosure may be carried out in an individual who has been diagnosed with CaP (i.e., therapeutic use). It may also be carried out in individuals who have a relapse or a high risk of relapse after being treated for CaP.
Inhibitors of the catalytic site of one or more 3α-oxidoreductases may be used alone, with other agents with similar effects, or with other modalities, including chemotherapeutic agents, surgery, radiation and the like. For example, inhibitors of the common catalytic site of one or more 3α-oxidoreductases may be used with dutasteride and/or abiraterone. Currently, no clinical inhibitors against these 3α-oxidoreductases are available. Therefore, inhibitors of the common catalytic site of one or more 3α-oxidoreductases may be used in combination with existing therapies like dutasteride to provide a new treatment strategy to block the key enzymatic steps of the frontdoor, primary and secondary backdoor pathways, which may decrease DHT levels better than ADT alone. Further reduction of tissue DHT levels by inhibiting the last step(s) in intracrine metabolism may improve response to ADT or induce re-remission of CRCP and improve survival of men with advanced CaP.
The following examples further describe the disclosure. These examples are intended to be illustrative and not limiting in any way.
This example: i) demonstrates that the 3α-oxidoreductases are expressed in AS-CaP and CRPC, ii) identifies the catalytic residues necessary to catalyze the terminal step of the primary backdoor pathway, androstanediol to DHT, and iii) provides evidence that combined SRD5A and 3α-oxidoreductase inhibition lowers DHT levels further than inhibition of either enzyme family alone.
Experimental Procedures
Cell Culture
Human CaP lines LAPC-4 (Klein et al., 1997, Nat Med 3, 402-408), LNCaP-RPCI (LNCaP) (Horoszewicz et al., 1983, Cancer Res 43, 1809-1818), PC-3 (ATCC, Manassas, Va.) and LNCaP-C4-2 (C4-2) cells (Thalmann et al., 1994; Wu et al., 1994, Cancer Res 54, 2577-2581) were cultured in RPMI 1640 (Mediatech, Inc., Manassas, Va.). CWR-R1 cells (Gregory et al., 2001, Cancer Res 61, 2892-2898) was cultured using Richter's Improved media (Corning). CV-1 monkey kidney cells, DU145 (Mickey et al., 1980, Prog Clin Biol Res 37, 67-84) and VCaP cells (ATCC) were cultured in DMEM (Corning, Corning, N.Y.). RPMI and DMEM media were supplemented with 10% fetal bovine serum (FBS, Corning) and 2 mM glutamine (Corning). CWR-R1 cells were cultured in Richter's Improved Media (Corning) supplemented with 1% epidermal growth factor (Thermo Fisher Scientific, Waltham, Mass.), 1% insulin-transferrin-sodium selenite supplement (Roche, Indianapolis, Ind.), 1% nicotinamide (Calbiochem, Billerica, Mass.) and 2% FBS. Androgen-dependent CWR22 (Wainstein et al., 1994, Cancer Res 54, 6049-6052) and castration-recurrent CWR22 (rCWR22) (Nagabhushan et al., 1996, Cancer Res 56, 3042-3046) human CaP xenografts were propagated in immunocompromised nude mice.
All cell lines and xenografts were authenticated using genomic profiling in the Genomic Shared Resource. DNA profiles were acquired using 15 short tandem repeat (STR) loci and an amelogenin gender-specific marker. Test and control samples were amplified using the AmpFLSTR® Identifiler® Plus PCR Amplification Kit (Thermo Fisher Scientific, Waltham, Mass.) using the Verti 96-well Thermal Cycler (Applied Biosystems, Foster City, Calif.) in 9600 Emulation Mode (initial denature: 95° C. 11 min, 28 cycles of denature: 94° C. 20 sec and anneal/extend: 59° C. 3 min, final extension: 60° C. 10 min and hold: 12° C.). PCR products were evaluated using the 3130xl Genetic Analyzer (Applied Biosystems) and analyzed using GeneMapper v4.0 (Applied Biosystems). Eight of the 15 STRs and amelogenin from the DNA profile for the cell lines were compared to the ATCC STR database (atcc.org/STR %20Database.aspx?slp=1) and the DSMZ combined Online STR Matching Analysis (dsmz.de/fp/cgi-bin/str.html). All matches above 80% were considered the same lineage.
LAPC-4 cells were plated at 1.2×105/well and CV-1 cells at 1×104/well in 6-well tissue culture plates (Corning). Media and cell pellets from two 6-well plates were combined to generate 1 media and 1 cell pellet sample for liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. LAPC-4 cells were transfected using the Effectene Transfection Kit (Invitrogen, Grand Island, N.Y.). Forty-eight h after transfection, growth media was removed and LAPC-4 cells were washed once with Dulbecco's phosphate buffered saline (PBS, Corning). LAPC-4 cells were treated with serum-free complete media (SFM, Corning) alone or with 1 nM T, 20 nM DIOL 20 nM 5α-androstan-3α-ol-17-one (androsterone; AND) (Steraloids, Newport, R.I.) or 1 μM dutasteride (Selleckchem, Houston, Tex.) for 12 h. CV-1 cells were transfected using X-tremeGene HP transfection reagent (Roche Diagnostics Corporation, Indianapolis, Ind.). After 48 h, growth media were aspirated, CV-1 cells were washed once with PBS and incubated in SFM alone or with 20 nM AND (Steraloids) for 12 h.
After 12 h treatment, media (total 24 mL) were collected in 50 mL conical tubes (Corning). Cells were released using trypsin and collected in 15 mL conical tubes (Corning). The cells were washed 3 times using PBS, re-suspended in 1 mL PBS and 5% of the cell suspension was removed for protein concentration measurement and western blot analysis. The remaining 95% of the cell suspension was centrifuged and the supernatant was removed and discarded. Cell pellets were stored at −80° C. until analyzed using LC-MS/MS.
Constraint-Based Multiple Protein Alignment Tool (COBALT)
The COBALT protein sequence alignment tool was accessed using the National Center for Biotechnology (NCBI) website (ncbi.nlm.nih.gov/tools/cobalt/cobalt.cgi). Accession numbers for the 3α-oxidoreductases, HSD17B6, RDH16, DHRS9 and RDH5, were acquired using the NCBI protein database (ncbi.nlm.nih.gov/protein) and UniProtKB (uniprot.org/). Amino acid sequences of the four 3α-oxidoreductases were analyzed using COBALT and compared to other 3α-oxidoreductases and the SRD5A and CYP17 families to determine whether the catalytic site was conserved and specific to HSD17B6, RDH16, DHRS9 and RDH5.
Site-Directed Mutagenesis
Site-directed mutagenesis was performed using the QuikChange® Lightning Site-Directed Mutagenesis Kit (Strategene, Foster City, Calif.), using Strategene's protocol. pCMV6-entry expression plasmids with C-terminal MYC-DDK tag encoded with HSD17B6, RDH16, DHRS9 or RDH5 were purchased from Origene (Origene, Rockville, Md.). 3α-oxidoreductase primers (Integrated DNA Technologies, Coralville, Iowa) were used to delete the catalytic site (Δcat) or generate double mutations (Y→F, K→R) (Table 1). Plasmids were purified using PureYield Plasmid Miniprep System (Promega, Madison, Wis.) and sequenced at the Roswell Park Cancer Institute Genomic Shared Resource. Polymerase chain reaction (PCR) for plasmid sequencing was performed using plasmid templates and Big Dye Terminator v3.1 Master Mix Kit (Life Technologies, Carlsbad, Calif.). PCR products were purified using Sephadex-G50 (Sigma-Aldrich, St. Louis, Mo.) into multiscreen HV plates (Thermo Fisher Scientific). Eluted samples were analyzed using 3130xl ABI Prism Genetic Analyzer. Sequence data were analyzed using Sequencing Analysis 5.2 software (Life Technologies).
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
RNA extraction was performed using the RNeasy Plus Mini Kit (Qiagen, Valencia, Calif.). Samples generated from 9 cell lines were plated at 1×106 cells/T25 cell culture flask (Corning). Cells were harvested using 0.05% trypsin and washed 3 times using PBS. PBS was removed and RLT lysis buffer was added to lyse the cell pellets. Frozen tissues from 2 xenografts (CWR22 and rCWR22) were Dounce homogenized in RLT lysis buffer. Lysates were passed through QIAshredder columns and RNA was extracted using RNeasy spin columns. Genomic DNA contamination was assessed using PCR and intron spanning GAPDH primers. Genomic DNA contamination was removed using a DNA-free DNA Removal Kit (Life Technologies). RNA was analyzed using PCR after DNase treatment to confirm genomic DNA was removed.
First strand complementary DNA (cDNA) was generated using 2 μg RNA and the High-Capacity cDNA Reverse Transcription Kit (10× RT Buffer, 10× Random Primers, 25× 100 mM deoxyNTP mix and 50 U/μL MultiScribe-Reverse Transcriptase; Applied Biosystems) and RNAse inhibitor in 10 μL reactions. The Primer Quest Primer Design Tool was used to design qRT-PCR primers (Integrated DNA Technologies) (Table 1).
qRT-PCR reactions included 12.5 μL of SYBR Green PCR Master Mix (Applied Biosystems), 0.1 μL of 10 mM forward and reverse primers, 2.5 μL of 100 ng/μL cDNA (250 ng final concentration) and 9.8 μL distilled deionized (dd-H2O) for a final reaction volume 25 μL. Reactions were performed in 96-well plates. Gene expression was analyzed using 7300 Real Time System (Applied Biosystems). The qRT-PCR reaction parameters were 95° C. for 30 sec, 60° C. for 30 sec repeated 39 times, 95° C. for 5 sec and melt curve 65° C.-95° C. All procedures were performed with 3 technical replicates and 3 biological replicates. Cycle threshold (Ct) values were normalized against (32 microglobulin (B2M) that was selected based on unchanged B2M expression in SFM (data not shown). Ct values for negative RT controls and no template controls were reported as undefined. Relative gene abundance was calculated using 2{circumflex over ( )}-(normalized Ct).
LC-MS/MS
Cell pellet and media samples were analyzed over 9 runs for 5 androgens T, DHT, dehydroepiandrosterone, ASD and AND using a validated LC-MS/MS method. 5α-dione was also measured using this assay and data were included although results did not pass the strict validation acceptance criteria used for other androgens. Study samples were quantitated using aqueous-based spiked calibration standards and pre-spiked quality control samples prepared in 2× charcoal-stripped human postmenopausal female plasma (Bioreclamation, LLC, Westbury, N.Y.). Performance data for calibrators, quality controls and calibration ranges were listed in Table 2. Values below the lower limit of quantitation were treated as zero.
Androgen concentrations (pmoles/mg protein) in cell lysates measured using LC-MS/MS (ng/mL) were multiplied by the total volume of the lysate (1 mL), normalized by the total amount of protein of the cell pellet (mg), divided by the molecular weight of the androgen (ng/nmole), and converted to pmoles. Media androgen concentrations (ng/mL) were multiplied by the total volume of media (24 mL), normalized against total protein of the cell culture (mg), divided by the molecular weight of the androgen (ng/nmole) and converted to pmoles. Cell pellet and media androgen concentrations were reported combined in Results and separately in Supplemental Results. Experiments were performed in triplicate.
Western Blotting
Cells removed from −80° C. storage were resuspended in ubiquitin extraction lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 5 mM EDTA, 1% NP40, 0.5% sodium deoxycholate (all from Fisher, Pittsburgh, Pa.)) and 0.1% SDS (Quality Biological, Gathersburg, Md.). Halt Protease Inhibitor Cocktail (Sigma) was added to the ubiquitin lysis buffer just before cells were lysed. Cells were freeze-thawed three times and centrifuged at 14,000×g for 15 min. Supernatants were transferred to clean microfuge tubes. Protein was quantified using the Protein Determination Kit (BioRad) and analyzed in flat bottom 96-well plates using an EL800 University Microplate Reader (BioTek Instruments) and KC Junior software (Bio-Tek Instruments). SDS-polyacrylamide gel electrophoresis (PAGE) was performed using 4-15% Mini Trans-Blot cell (BioRad). Protein was transferred to Immuno-Blot PVDF membranes for Protein Blot (BioRad) and blocked in 5% milk in Tris-buffered saline with Tween 20 (TBST, Amersham Bioscience, GE Healthcare Bio-Sciences, Pittsburgh, Pa.) for 30 min.
Membranes were incubated with DDK targeted antibody (Origene) 1:1000 overnight at room temperature. After incubation, blots were washed three times with TBST (Amersham Bioscience) for 10 min each. Washed blots were incubated with goat anti-mouse secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, Pa.) 1:1000 for 1 h at room temperature. Blots were washed with TBST three times for 10 min each and protein expression was measured using the Pierce ECL Western Blotting Substrate (Life Technologies). Immunoblots were washed with TBST, blocked in 5% milk in TBST, reprobed for tubulin (1:1000 for 1 h at room temperature; Abcam, Cambridge, Mass.) and incubated with goat anti-rabbit secondary antibody (1:1000 for 1 h at room temperature; Jackson ImmunoResearch Laboratories).
Tissue Microarray (TMA) Construction
Matched androgen-stimulated benign prostate (AS-BP) and androgen-stimulated CaP (AS-CaP) tissue specimens were collected from 36 patients who underwent radical prostatectomy. CRPC specimens were collected from 36 patients who underwent transurethral resection of the prostate for urinary retention from CaP that recurred during ADT. Specimens were collected between 1991 and 2011 at the Roswell Park Cancer Institute or the University of North Carolina (Chapel Hill, N.C.). TMAs were constructed (0.6 millimeter tissue cores) from formalin-fixed, paraffin-embedded donor blocks from each patient, which was guided by RPCI or UNC genitourinary pathologists. TMAs contained control tissue from lung, tonsil, liver, kidney, colon, spleen, cervix, thyroid, ovary, testis, myometrium and brain.
TMAs were constructed using the same process on tissues collected from a randomized, double-blind, placebo-controlled clinical trial of selenium supplementation and finasteride treatment of patients with CaP prior to robotic prostatectomy (Selenium and Finasteride Pre-Treatment Trial ID: NCT00736645). Forty-seven patients scheduled for radical prostatectomy were randomized into one of four treatment groups: placebo, finasteride, selenium or combination finasteride and selenium.
Immunohistochemistry (IHC)
TMA sections were de-paraffinized, rehydrated under an alcohol gradient and antigen retrieved using Reveal Decloaker (Biocare Medical, Concord, Calif.) for 30 min at 110° C. and 5.5-6.0 psi. Sections were immunostained for the four 3α-oxidoreductases and AR as described (Table 3). Enzymatic activity was assayed using 3,3′-Diaminobenzidine (Sigma-Aldrich) and sections were counterstained with hematoxylin (Vector Laboratories, Burlingame, Calif.). Sections were dehydrated and mounted using permanent mounting medium. Section images were collected using a Leica DFC0425C camera mounted on a Leica DMRA2 microscope (Leica Microsystems Inc., Buffalo Grove, Ill.). Protein expression was determined by three scorers who assessed the immunostain intensity and assigned values between zero (no immunostain) and three (dark immunostain) for 100 cells per core that generated a final score between zero and 300.
Statistical Analysis
IHC and qRT-PCR expression data were modeled as a function of tissue type (AS-BP, AS-CaP or CRPC) or cell line (VCaP, LNCaP, LAPC-4, C4-2, PC-3, DU145, CWR-R1, CWR22 or rCWR22). Androgen concentrations were measured using LC-MS/MS and modeled for cell pellets, media and both as a function of enzyme (control, HSD17B6, RDH16, DHRS9 or RDH5), treatment (SFM, T, DIOL, AND or dutasteride), expressed wild-type, Δcat or Y→F, K→R mutant enzymes, interaction terms and random (replicate or subject) effects using a linear mixed model. The factors, factor levels, interaction terms and random effects included in each model depended on the specific experiment and research question addressed. Mean differences were evaluated using Dunnett or Tukey-Kramer adjusted F-tests about the appropriate linear contrasts of model estimates. All model assumptions were verified graphically using quantile-quantile and residual plots, with transformations applied when appropriate. All analyses were conducted in SAS v9.4 (Cary, N.C.) at a nominal significance level of 0.05.
Additional Methods
Cell pellets were resuspended in HPLC-grade water and vortexed or sonicated to disrupt cell membranes to obtain a homogeneous suspension. Samples were extracted using 0.25 ml quality control, plasma blank or sample in 0.75-2.0 mL HPLC-grade water, 0.1 ml internal standard (IS) solution (75.0/225 pg/mL d3-T/d3-DHT) and 4 mL methyl-tert-butyl ether (MTBE, Omnisolve®, EMD Milipore, Billerica, Mass.) in glass screw-top tubes. Calibrators were prepared using 50 μl spiking solution prepared in 75% methanol and added to the extraction tube. Either the entire 1 mL cell pellet suspension was added to the extraction tube and the original container rinsed with 25% methanol in water or samples were volume and compositionally corrected. Tubes were capped with Teflon-lined caps, vortexed, rotated 15 min and centrifuged using a Sorvall model RT6000B centrifuge (Thermo Scientific) at 2,800 rpm and 4° C. for 15-30 min to separate liquid phases. The aqueous phase was frozen in a dry ice/acetone bath and MTBE layer was poured into a clean glass conical tube. MTBE was evaporated at 37° C. with nitrogen and the residue was reconstituted with 60% methanol. The suspension was centrifuged using Heraeus Multifuge X3R centrifuge (Thermo Scientific) at 2,800 rpm and 4° C. for 5 min to separate insoluble materials. An aliquot of the supernatant was injected.
LC-MS/MS analysis of the extracted samples was performed using a Prominence UFLC System (Shimadzu Scientific Instruments, Kyoto, Japan) a QTRAP® 5500 mass spectrometer (AB Sciex, Framingham, Mass.) with an electrospray ionization source and two 10-port switching valves (Model EPC10W Valco Instruments Co. Inc., Houston, Tex.). The first switching valve was mounted in the column oven and was used to perform inline sample cleanup. The second valve functioned as a divert valve to switch the column eluent between waste and the mass spectrometer. Chromatographic separation was achieved using a Phenomenex® Luna® C18 (2) column (part number 00F-4251-B0) preceded by a Phenomenex® SecurityGuard™ cartridge (C18, part number AJ0-4286). The HPLC column was maintained at 60° C. and flow rate was 175 μL/min using a biphasic gradient. Mobile phase A was 65% methanol containing 400 μL 1 M ammonium formate and 65 μL concentrated formic acid per liter. Mobile phase B was 100% methanol containing 400 μL 1 M ammonium formate and 65 concentrated formic acid per liter.
Analytes were detected using multiple reaction monitoring in positive ion mode controlled by AB SCIEX Analyst® software, version 1.6.2 (AB Sciex). Mass spectrometer conditions were ion spray voltage 5,250 volts, turbo gas temperature 700° C., gas 1=65, gas 2=60, curtain gas=20, collision-associated dissociation gas medium and unit mass resolution for Q1 and Q3. Nitrogen was used for all gases and voltages for maximum parent/fragment ion pair intensities were optimized using direct infusion and flow injection analysis. Calibration curves were generated using analyte/IS area response ratios versus nominal concentrations (ng/mL) and weighted linear regressions with a weighting factor of 1/concentration2. The IS used for T, ASD and DHEA was d3-T and d3-DHT was used for DHT and AND. Back-calculated concentrations were generated using the formula x=(y−b)/m where x is the back-calculated concentration, y is analyte/IS ratio, b is y-intercept and m is slope. Calibrator and quality control acceptance criteria required all acceptable concentrations to have accuracy deviations ≤15% from the nominal concentration and relative standard deviation criteria (% RSD)≤15%, except at the lower limit of quantitation (LLOQ), listed in Table 2, which was allowed 20% deviation for both parameters. Values below the LLOQ (BLQ) were treated as 0.
Results
3α-oxidoreductase enzymes share a conserved catalytic site. The primary backdoor pathway uses one or more of four 3α-oxidoreductases to convert AND to 5α-dione or DIOL to DHT (
HSD17B6, RDH16, DHRS9 and RDH5 were expressed in clinical CaP. IHC was performed using TMAs that contain clinical specimens of AS-BP, AS-CaP and CRPC collected from 72 patients to assess 3α-oxidoreductase expression. IHC showed that HSD17B6, RDH16, DHRS9 and RDH5 were expressed in AS-BP, AS-CaP and CRPC (
3α-Oxidoreductase Gene Expression Varied Among CaP Cell Lines
Although 3α-oxidoreductases were detected in clinical samples using IHC, they were not detectable in CaP cell lines using western blot analysis. Therefore, qRT-PCR was performed to determine 3α-oxidoreductase, SRD5A and AR gene expression profiles in CaP cell lines and CWR22 and rCWR22 human CaP xenografts. RDH5 mRNA levels were higher than the expression in the other three 3α-oxidoreductases in all cell lines except VCaP, PC-3 and DU145 cells (
DHT Levels Increased when RDH16, DHRS9 or RDH5 were Expressed in LAPC-4 Cells
The effect of 3α-oxidoreductase expression on DHT levels was determined in the androgen-sensitive LAPC-4 cell line that expressed wild-type AR and RDH5 (
LC-MS/MS analysis revealed that LAPC-4 cells transfected with empty plasmid in SFM (medium without exogenous androgen) produced low levels of DHT (0.0211 pmoles/mg protein) (
LAPC-4 cells with empty plasmid treated with DIOL produced higher levels of DHT compared to SFM treated LAPC-4 cells with empty plasmid (
DHT levels were higher (p=0.024) when LAPC-4 cells with empty plasmid were treated with T (
5α-dione was produced when LAPC-4 cells with empty plasmid were treated with DIOL or AND (
Catalytic amino acid substitution or deletion impaired 3α-oxidoreductase activity. Site-directed mutagenesis of the 3α-oxidoreductase catalytic residues confirmed Y176/175 and K179/180 were essential for 3α-oxidoreductase activity for all four enzymes. The mutants included Δcat (deletion of the catalytic residues) or Y176F for HSD17B6, RDH16, DHRS9 or Y175F for RDH5 and K180R for HSD17B6, RDH16 and DHRS9 or K179R for RDH5. Rationale for the Y→F mutation was rested on their similarity in size but difference in an essential hydroxyl group. This mutation was not expected to alter protein folding but would affect enzyme activity. The K→R mutation was chosen because R would maintain a positive charge but was not expected alter protein folding.
qRT-PCR confirmed that CV-1 cells had low endogenous AR and 3α-oxidoreductase mRNA levels that suggests RDH5 converts AND to 5α-dione in control CV-1 cells (
CV-1 treated with AND produced only a small amount of 5α-dione that was measurable only in the media (
3α-oxidoreductase expression in AS-BP and CaP specimens from research subjects treated with finasteride. To address the clinical relevance of the 3α-oxidoreductases, LC-MS/MS was applied to tissues obtained from a randomized double-blind placebo-controlled clinical trial of selenium supplementation and finasteride treatment of research subjects with CaP prior to radical prostatectomy (Selenium and Finasteride Pre-Treatment Trial, 1104607). Research subjects who received finasteride alone or in combination with selenium were compared to research subjects who received selenium alone or placebo. Research subjects treated with finasteride had decreased CaP tissue levels of DHT in both benign and malignant macro-dissected samples, although DHT levels remained sufficient to activate AR (data not shown). TMAs generated from the clinical trial were sectioned and analyzed using IHC. HSD17B6, RDH16, DHRS9 and RDH5 were expressed in AS-BP and AS-CaP (
Combination dutasteride and 3α-oxidoreductase mutants decreased DHT greater than dutasteride alone. Primary backdoor DHT synthesis may facilitate CaP resistance to 5α-reductase inhibition. Therefore, simultaneous inhibition of the terminal steps of the frontdoor and primary backdoor pathways could lower DHT levels more effectively than targeting either terminal step alone. LAPC-4 cells had SRD5A activity and dutasteride treatment decreased LAPC-4 DHT levels. LAPC-4 cells also were capable of backdoor DHT synthesis using 3α-oxidoreductases to convert DIOL to DHT (
DHT levels were higher in LAPC-4 cell pellets that overexpressed RDH16 (p<0.001) or DHRS9 (p<0.001) compared to LAPC-4 cell pellets with empty plasmid (
Empty plasmid, or plasmids for over-expression of RDH16 wild-type or RDH16-Y176F, K180R, were expressed into VCaP, C4-2 or CWR-R1 cells and DHT levels were measured using LC-MS/MS. DHT levels were similar in VCaP cells in SFM treated with or without dutasteride, which suggested that dutasteride treatment did not lower VCaP DHT levels (
Western blot analysis demonstrated wild-type, Δcat or Y→F, K→R mutant 3α-oxidoreductase expression in the cell lines (
The findings provide a proof of principle that 3α-oxidoreductases enhance DHT synthesis in CaP cells and inhibition of 3α-oxidoreductases impairs the ability of CaP cells to synthesize DHT using the primary backdoor pathway (
Experiments could not be performed using endogenous 3α-oxidoreductases because enzyme expression was so low in CaP cell lines. Therefore, 3α-oxidoreductases were expressed transiently in CaP and CV-1 cells. Androgen levels among replicates as determined using our LC-MS/MS analytical system were consistent across nine analytical runs conducted over a twenty month period. Western blot analysis showed expression levels were consistent among wild-type enzymes. Western blots also showed 3α-oxidoreductase mutant expression was lower than the expression of wild-type 3α-oxidoreductases that suggested amino acid substitutions may impair post-translational modification. However, sufficient enzyme was present based on the reproducibility of the replicates and differences in androgen metabolism observed among CaP cells transfected with control, wild-type or mutant 3α-oxidoreductases.
LC-MS/MS results were reliable over time and across replicates because the extracted calibration standards and plasma quality controls used to control and assess the quality of each LC-MS/MS analysis had an overall mean accuracy of 100% and 97.9%, respectively for the androgens analyzed in CaP cell pellets and media over nine independent sets of experiments. The LC-MS/MS method used for these studies was limited to six androgens. However, glucuronidated or sulfated androgens or androgen metabolites with activity in the glucocorticoid pathway were not measured. The LC-MS/MS method could not measure DIOL because DIOL did not display a mass spectrum sufficiently different from other androgens. Therefore, AND conversion to 5α-dione was used to measure individual enzyme activity for the expression studies in CV-1 cells. The studies suggested that the conversion of AND to 5α-dione is important clinically. The combination of dutasteride treatment and 3α-oxidoreductase mutation showed DHT levels were suppressed for 12 h. Clinical effectiveness will require longer studies of any potential inhibitor of the four 3α-oxidoreductases alone or in combination with dutasteride.
Taken together, the data [1] show that 3α-oxidoreductases are expressed in AS-BP, AS-CaP and CRPC; [2] demonstrate the catalytic residues necessary for the terminal step of the primary backdoor pathway, DIOL to DHT, are essential to all four 3α-oxidoreductases; and [3] provide evidence that combined SRD5A and 3α-oxidoreductase blockade lowered DHT levels more effectively than inhibition of either enzyme family alone. Inhibitors against the 3α-oxidoreductases are not yet available for clinical use and need to be identified. A new treatment strategy to block the key enzymatic steps of the frontdoor and primary and secondary backdoor pathways may decrease DHT levels more effectively than ADT alone. Further reduction of tissue DHT by inhibiting the last step of intracrine DHT synthesis should improve the clinical response to ADT or induce re-remission of CRPC and improve survival of men with advanced CaP.
While the present invention has been described through embodiments, these are intended to be illustrative and routine modifications are intended to be within the scope of the disclosure.
This application is a continuation-in-part of U.S. Non-Provisional patent application Ser. No. 16/088,224, filed on Sep. 25, 2018, which is a National Phase application of International application no. PCT/US2017/024322, filed on Mar. 27, 2017, which claims priority to U.S. Provisional Patent application No. 62/313,261, filed on Mar. 25, 2016, the disclosures of each of which are incorporated herein by reference.
This invention was made with government support under grant numbers CA016056 and CA77739 awarded by the National Cancer Institute and grant number W81XWH-15-0409 awarded by the U.S. Army Medical Research Acquisition Activity. The government has certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 62313261 | Mar 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16088224 | Sep 2018 | US |
| Child | 17239196 | US |
